| 2000-01 |
Established in Toyota City, Aichi Prefecture, to conduct research and development of a novel anticancer agent with minimal impact on normal cells, based on findings related to the G2 checkpoint. |
| 2000 |
Established CanBas Co., Ltd. in Toyota City, Aichi Prefecture, in 2000. |
| 2000 |
Established CanBas Co., Ltd. in Toyota, Aichi. |
| 2001-01 |
Opened a research laboratory within the incubation facility attached to the Shizuoka Numazu Industrial Technology Center in Ōoka, Numazu City, Shizuoka Prefecture. |
| 2001-01 |
Established a research institute in Numazu City, Shizuoka Prefecture. |
| 2001-01 |
Set up the Laboratory in Numazu, Shizuoka. |
| 2002-03 |
Established a Scientific Advisory Board (SAB). |
| 2002-04 |
Relocated the headquarters and research laboratory to Tōyōchō, Numazu City, Shizuoka Prefecture, and established an animal testing facility within the Shizuoka Numazu Industrial Technology Center. |
| 2002-04 |
Relocated headquarters and research institute to Toriyoko‑cho, Numazu City, Shizuoka Prefecture; established an animal testing facility within the Numazu Industrial Technology Center, Shizuoka Prefecture. |
| 2005-05 |
Initiated a Phase 1 clinical trial of CBP501 monotherapy in the United States. |
| 2005-05 |
Initiated a single-agent Phase 1 clinical trial of CBP501 in the United States. |
| 2005-05 |
Initiated CBP501 single-drug Phase 1 clinical study in the US. |
| 2006-03 |
Moved the animal testing facility from the incubation facility attached to the Shizuoka Numazu Industrial Technology Center to a site adjacent to the headquarters in Tōyōchō, Numazu City, Shizuoka Prefecture. |
| 2006-10 |
Commenced a Phase 1 clinical trial of the combination of CBP501 and cisplatin in the United States. |
| 2006-10 |
Initiated a Phase 1 clinical trial of CBP501 in combination with cisplatin in the United States. |
| 2006-10 |
Initiated CBP501 Phase 1 clinical study in two drug combinations with Cisplatin in the US. |
| 2007-03 |
Entered into a joint venture agreement with Takeda Pharmaceutical Company Limited regarding CBP501 and its backup compounds. |
| 2007-03 |
Entered into a joint development agreement with Takeda Pharmaceutical Company for CBP501. |
| 2007-03 |
Entered into CBP501 Joint Development Agreement with Takeda. |
| 2008-03 |
Initiated CBP501 Phase 1 clinical study in three drug combinations with Cisplatin and Pemetrexed in the US. |
| 2008-05 |
Started a Phase 1 clinical trial of the triple combination of CBP501, cisplatin, and pemetrexed in the United States. |
| 2008-05 |
Initiated a phase 2 clinical trial of CBP501 in combination with cisplatin and pemetrexed in the United States. |
| 2008-11 |
Initiated a Phase 2 clinical trial of the triple combination of CBP501, cisplatin, and pemetrexed for malignant pleural mesothelioma in the United States. |
| 2008-11 |
Initiated a phase 2 clinical trial of CBP501 in pleural mesothelioma patients in the United States (combination with cisplatin and pemetrexed). |
| 2008-11 |
Initiated CBP501 Phase 2 clinical study in patients with MPM in three drug combinations with Cisplatin and Pemetrexed in the US. |
| 2009-06 |
Commenced a Phase 1b trial of the combination of CBP501, cisplatin, and nivolumab (Opdivo). |
| 2009-06 |
Initiated a phase 2 clinical trial in the United States combining CBP501, cisplatin, and pemetrexed for non‑small cell lung cancer. |
| 2009-09 |
Listed shares on the Tokyo Stock Exchange Mothers market. |
| 2009-09 |
Listed on the Tokyo Stock Exchange Mothers market. |
| 2009-09 |
Went public on the Tokyo Stock Exchange Mothers Market. |
| 2010-06 |
Completed enrollment for the expansion phase of the Phase 2 clinical trial of CBP501 targeting pancreatic cancer. |
| 2010-06 |
Presented Phase 1b trial data of CBP501 at ASCO. |
| 2010-06 |
Terminated the joint development agreement for CBP501 with Takeda Pharmaceutical Company. |
| 2010-06 |
Terminated the joint commercialization agreement with Takeda Pharmaceutical Company concerning CBP501 and its backup compound. |
| 2010-06 |
Terminated CBP501 Joint Development Agreement with Takeda Pharmaceutical Co., Ltd. |
| 2010-09 |
Relocated the headquarters, research laboratory, and animal testing facility to Otemachi, Numazu City, Shizuoka Prefecture (current location). |
| 2010-09 |
Consolidated headquarters, research institute, and animal testing facility and relocated to Ohtemachi, Numazu City, Shizuoka Prefecture (current location). |
| 2012-01 |
Received orphan drug designation from the U.S. FDA for CBP501 targeting mesothelioma. |
| 2012-01 |
CBP501 received orphan drug designation from the U.S. FDA (eligible for MPM). |
| 2012-01 |
CBP501 received orphan drug designation from FDA for MPM. |
| 2012-06 |
Announced at ASCO that CBP501 achieved the primary endpoint in the Phase 2 clinical trial for malignant pleural mesothelioma. |
| 2012-06 |
Achieved the primary endpoint in the phase 2 clinical trial of CBP501. |
| 2012-06 |
CBP501 achieve the primary endpoint of the Phase 2 clinical study in patients with Malignant Pleural Mesothelioma (MPM). |
| 2013-04 |
Published preliminary results of the Phase 2 clinical trial of CBP501 for non‑small cell lung cancer. Although the primary endpoint was not met, a significant effect was suggested in a key secondary endpoint in a specific patient subgroup. |
| 2013-04 |
Published preliminary data from a phase 2 clinical trial of CBP501 in patients with non‑small cell lung cancer (NSCLC). |
| 2013-04 |
Published preliminary data from CBP501 Phase 2 clinical study in patients with Non Small Cell Lung Cancer (NSCLC). |
| 2014-12 |
Signed a licensing agreement with Stemline Corporation in the United States regarding CBS9106. |
| 2014-12 |
Granted a license for CBS9106 to Stemline (excluding Japan, China, Taiwan, and South Korea). |
| 2014-12 |
Granted CBS9106 license (except for Japan, China, Taiwan and South Korea) to Stemline. |
| 2016-02 |
Entered into a joint research agreement with the University of Tokyo Hospital (National University Corporation) for pharmacological efficacy testing using a pancreatic cancer induction model mouse. |
| 2016-03 |
Started a Phase 1 clinical trial targeting solid tumors with CBS9106 (development code SL-801, generic name Felezonexor) in partnership with Stemline. |
| 2016-03 |
Stemline commenced a phase 1 clinical trial of CBS9106 (SL‑801) for solid tumors. |
| 2016-03 |
Stemline initiated CBS9106 (SL-801) Phase 1 study for solid tumors. |
| 2016-04 |
Entered into a joint research agreement with the Shizuoka Prefecture Industrial Promotion Foundation (Pharma Valley Project) for drug discovery screening using a compound library. |
| 2016-04 |
Entered into a joint research (screening) agreement with Fuji Pharmaceutical. |
| 2016-04 |
Joint Research (screening) Agreement with Fuji Pharma Valley Project. |
| 2016-06 |
Entered into a joint research agreement with the Shizuoka Prefecture Industrial Promotion Foundation (Pharma Valley Project) regarding IDO/TDO inhibitors. |
| 2016-06 |
Signed a joint research agreement with Shizuoka University for IDO/TDO. |
| 2016-06 |
IDO/TDO Joint Research Agreement with University of Shizuoka. |
| 2016-06 |
CBP501 Phase 1b data published at ASCO. |
| 2017-04 |
Initiated a Phase 1b trial combining CBP501, cisplatin, and nivolumab (Opdivo). |
| 2017-04 |
Initiated a phase 1b clinical trial of CBP501 (dose‑escalation cohort) in the United States (combination with cisplatin and nivolumab). |
| 2017-04 |
Initiated CBP501 Phase 1b clinical study (dose finding cohort) with CDDP and nivolumab combination in the US. |
| 2018-08 |
Modified the license agreement with Stemline for CBS9106, expanding the target region to worldwide, including Japan, China, Taiwan, and South Korea. |
| 2018-08 |
Granted a global license for CBS9106 to Stemline. |
| 2018-08 |
Granted CBS9106 global license to Stemline Therapeutics, Inc. |
| 2020-06 |
Completed enrollment of the pancreatic cancer cohort in the expanded Phase 1b trial of CBP501. |
| 2020-06 |
Presented Phase 1b trial data of CBP501 at ASCO. |
| 2020-06 |
Presented phase 1b data of CBP501 at ASCO. |
| 2020-08 |
Received grant funding for the 2020 (Reiwa 2) Medical Device Industry Infrastructure Strengthening Project focusing on COVID-19 therapeutics targeting immune responses. |
| 2021-04 |
Received approval from the U.S. FDA to commence a phase 2 clinical trial targeting third‑line treatment for pancreatic cancer with CBP501. |
| 2021-10 |
Opened a clinical site for the phase 2 trial of CBP501. |
| 2021-12 |
CBP501 Phase 2 clinical trial site FPI (first patient enrollment) |
| 2022-02 |
Completed a Phase 1 clinical trial targeting solid tumors with CBS9106 (development code SL-801, generic name Felezonexor) in partnership with Stemline. |
| 2022-04 |
Moved from the Mothers market to the Growth market of the Tokyo Stock Exchange due to a review of market classifications. |
| 2022-04 |
Extended the terms of the joint research agreement with the University of Tokyo. |
| 2023-06 |
Obtained a patent for IDO/TDO inhibitors from the Japan Patent Office. |
| 2024-02 |
Received approval from the U.S. FDA to commence Phase 2b clinical trials of CBP501. |
| 2024-08 |
CBP501 designated as an orphan drug by the European Medicines Agency (EMA). |
